Why Fortress Biotech, Inc. (FBIO) Stock Gained Sharply Today

Fortress Biotech, Inc. (NASDAQ:FBIO) is one of the best performers on the stock market today. At current price of $2.12, the shares have already added 0.16 points (8.16% higher) from its previous close of $1.96. Should you buy or avoid them? The stock sets an active trading volume day with a reported 381326 contracts so far this session. FBIO shares had a relatively better volume day versus average trading capacity of 667.67 thousand shares, but with a 39.05 million float and a 7.1% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for FBIO stock indicates that the average analyst price target is $11 per share. This means the stock has a potential increase of 418.87% from where the FBIO share price has been trading recently which is between $1.8123 and $2. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $11.

The shorts are running away from Fortress Biotech, Inc. (FBIO) stock. The latest set of short interest data was released on 28 February 2019, and the numbers show a drop in short interest in FBIO shares. While short interest still represents only 5.03% of FBIO’s float, the number of shares shorted have fallen by -227866. The number of shares shorted fell to 1734764 shares, down from 1962630 shares during the preceding fortnight. With average daily trading volumes at 334707 shares, days to cover increased to about 2.577497 days.

During the recent trading session for Fortress Biotech, Inc. (NASDAQ:FBIO), the company witnessed their stock rise $0.35 over a week and tumble down $-0.07 from the price 20 days ago. When compared to their established 52-week high of $5.36, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 03/21/18. The recent low of $0.49 stood for a -61.37% since 12/21/18, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 3.25 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.

Looking at the current readings for Fortress Biotech, Inc., the two-week RSI stands at 58.25. This figure suggests that FBIO stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current FBIO readings is similarly very revealing as it has a stochastic reading of 55.77% at this stage. This figure means that FBIO share price today is being neutral.

Technical chart claims that Fortress Biotech, Inc. (FBIO) would settle between $2.04/share to $2.11/share level. However, if the stock price goes below the $1.85 mark, then the market for Fortress Biotech, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $1.74 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.09. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.

Analysts at B. Riley FBR, Inc., assumed coverage of FBIO assigning Buy rating, according to their opinion released on February 28. Rodman & Renshaw, analysts launched coverage of Fortress Biotech, Inc. (NASDAQ:FBIO) stock with a Buy recommendation, according to their flash note issued to investors on July 11. Analysts at JMP Securities, made their first call for the equity with a Mkt Outperform recommendation, according to a research note that dated back to March 22.

FBIO equity has an average rating of 2, with the figure leaning towards a bullish end. 1 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 1 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 1 analysts rated Fortress Biotech, Inc. (NASDAQ:FBIO) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.

Moving on, FBIO stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/S ratio is 2.19 while for the average stock in the same group, the multiple is 6.59.